AU2023235307A1 - Combinations comprising metap2 inhibitors for the treatment of cancer - Google Patents

Combinations comprising metap2 inhibitors for the treatment of cancer Download PDF

Info

Publication number
AU2023235307A1
AU2023235307A1 AU2023235307A AU2023235307A AU2023235307A1 AU 2023235307 A1 AU2023235307 A1 AU 2023235307A1 AU 2023235307 A AU2023235307 A AU 2023235307A AU 2023235307 A AU2023235307 A AU 2023235307A AU 2023235307 A1 AU2023235307 A1 AU 2023235307A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
subject
administered
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023235307A
Other languages
English (en)
Inventor
Bradley J. CARVER
Peter Cornelius
Benjamin MAYES
James Shanahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SynDevRX Inc
Original Assignee
SynDevRX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SynDevRX Inc filed Critical SynDevRX Inc
Publication of AU2023235307A1 publication Critical patent/AU2023235307A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2023235307A 2022-03-16 2023-03-16 Combinations comprising metap2 inhibitors for the treatment of cancer Pending AU2023235307A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263320347P 2022-03-16 2022-03-16
US63/320,347 2022-03-16
US202263340726P 2022-05-11 2022-05-11
US63/340,726 2022-05-11
PCT/US2023/064550 WO2023178255A1 (en) 2022-03-16 2023-03-16 Combinations comprising metap2 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2023235307A1 true AU2023235307A1 (en) 2024-10-17

Family

ID=85979451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023235307A Pending AU2023235307A1 (en) 2022-03-16 2023-03-16 Combinations comprising metap2 inhibitors for the treatment of cancer

Country Status (9)

Country Link
US (1) US20260014194A1 (https=)
EP (1) EP4493181A1 (https=)
JP (1) JP2025509613A (https=)
KR (1) KR20240164549A (https=)
CN (1) CN119300818A (https=)
AU (1) AU2023235307A1 (https=)
CA (1) CA3245962A1 (https=)
MX (1) MX2024011197A (https=)
WO (1) WO2023178255A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102485537B1 (ko) * 2014-08-04 2023-01-05 메르크 파텐트 게엠베하 Metap-2 저해제로서의 피롤리디논 유도체
JP2022512826A (ja) * 2018-10-26 2022-02-07 シンデブルックス,インコーポレイティド MetAP2阻害剤のバイオマーカーとその応用

Also Published As

Publication number Publication date
CN119300818A (zh) 2025-01-10
US20260014194A1 (en) 2026-01-15
MX2024011197A (es) 2024-09-18
WO2023178255A9 (en) 2024-09-26
EP4493181A1 (en) 2025-01-22
WO2023178255A1 (en) 2023-09-21
KR20240164549A (ko) 2024-11-19
CA3245962A1 (en) 2023-09-21
JP2025509613A (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
EP4385571B1 (en) A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis
JP2025032212A (ja) MetAP2阻害剤のバイオマーカーとその応用
TW201919615A (zh) 用於治療tnbc的化合物
JP2021505571A (ja) 末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法
KR20250089532A (ko) 암 치료를 위한 serd의 조합
JP2021169534A (ja) 化学療法の改善
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
CN115135649A (zh) 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
JP2024542633A5 (https=)
JP2024502671A (ja) ピリド[1,2-a]ピリミジノン類似体の使用
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
US20260014194A1 (en) Combinations comprising metap2 inhibitors for the treatment of cancer
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
TW201244732A (en) Ezatiostat for treating multiple myeloma
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
JP4522261B2 (ja) ブドウ膜黒色腫の処置
AU2024304092A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
KR20250006934A (ko) 고형 종양을 치료하기 위한 이중 선택적 pi3k 델타 및 감마 억제제 및/또는 염-유도성 키나제 3 억제제
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
CN116327772A (zh) SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法
JP2022065212A (ja) 組織線維化による疾患の予防又は治療のための医薬
JP2010111582A (ja) リファンピシンを成分とする肝臓癌治療剤